



# Combining Omics and Cognitive Tests Data from SMC individuals, Artificial Intelligence Technology Identifies Genomic Biomarkers for Early Detection of Alzheimer's Disease.

Martin Kindermans, MSc<sup>1</sup>, **Mohammad Afshar, MD, PhD<sup>1</sup>**, Patrizia Andrea Chiesa, PhD<sup>2,3,4</sup>, Adrien Etcheto, MSc<sup>1</sup>, Simone Lista, PhD<sup>2,3,4</sup>, Pablo Lemercier<sup>2,3,4</sup>, Frédéric Parmentier, PhD<sup>1</sup>, Andrea Vergallo, MD<sup>2,3,4</sup>, Coralie Williams, MSc<sup>1</sup> and Harald Hampel, Prof., MD, PhD<sup>3</sup>

(1) Ariana Pharma, Paris, France

(2) Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HO, Boulevard de l'hôpital, F-75013, Paris, France

(3) Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, F-75013, Paris, France

(4) Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l'hôpital, F-75013, Paris, France

AAIC 2019, July 14-18  
Los Angeles, CA, U.S.

# Conflict of Interest Disclosure

---

**Mohammad Afshar** is employee and shareholder of Ariana Pharma


AAIC 2019, July 14-18  
Los Angeles, CA, U.S.

---

# Introduction

## Towards earlier detection of Alzheimer's disease

Number of AD cases will triple, healthcare cost will double by 2030



2018

2030

Source: World Alzheimer Report 2018

Early detection and management of some, if not all, future AD cases is critical

Focusing on profiles at risk for AD, but not yet affected, will help us



Today!

**The combination of DNA analysis and Artificial Intelligence is needed to analyze extensively characterized cohorts**

We need a cohort of subjects, not having AD, MCI, or other neurological/psychiatric disorder, but at risk, with extensive DNA information

# Introduction

## Preclinical Cohort of subjects with subjective memory complaints SMC


Study performed in a large-scale, university-based, monocentric cohort

Cognitively and physically normal Caucasian individuals with SMC  
SMC defined as positive response to both questions:

- Are you complaining about your memory?
- Is it a regular complaint which lasts more than 6 months?

- ✓ 318 subjects
- ✓ 70–85 years
- ✓ Subjective memory complaints
- ✓ Unimpaired cognition and memory

Extensive  
longitudinal  
characterization



Amyloid (18F-Florbetapir) PET Imaging

Brain MRI / fMRI imaging

Brain glucose-metabolism  
[18F-fluorodeoxyglucose (18F-FDG) PET]

Cognitive assessment


# Questions

Hibar *et al*, Nature 2015

**nature**  
International journal of science

Letter | Published: 21 January 2015



Common genetic variants influence human subcortical brain structures



**Can we identify genomic variants that are simultaneously linked to multiple types of endpoints?**

# Methodology

AI needed to address the data analytics challenge of “wide matrices” and very large number of hypothesis



Hypothesis free  
AI needed



# Association rules: finding strong relations missed by statistics



Many things!

N= 1000



N= 1000  
P=1%



N= 10  
**P=90%**



# Principles of KEM<sup>®</sup> Galois Lattices or Formal Concept Analysis

Association rules and interestingness measures are key drivers of the approach

## KEM<sup>®</sup>


- Unsupervised data mining tool based on Galois Lattices (Formal Concept Analysis)

## Association rules


- Comprehensively analyze complex datasets
- Reveal hidden relationships
- Derive new hypotheses

## Interestingness measures

- Measures all logical relations within a dataset
- Identifies the most relevant and powerful relations
- Decides if and how to use relations to answer a given question



# Positioning of KEM<sup>®</sup> and other data analysis techniques: avoiding over-fitting, data driven (rather than hypothesis) and interpretable



- KEM<sup>®</sup> vs. other data analysis techniques:
- 1. Unsupervised** (hypothesis-free) rather than supervised (e.g. optimizing a discrimination objective) to avoid over-fitting;
  - 2. Interpretable** (white box) rather than black box;
  - 3. Datamining** rather than statistical (frequentist).

\* **OLAP** – OnLine Analytic Processing // **KNN** – k-nearest neighbor algorithm // **ILP** – Inductive Logic Programming // **LGG** – Least General Generalizations // **SVMs** – Support Vector Machines

# Explainable AI: The next stage of human-machine collaboration

AUGUST 31, 2018



## RESEARCH REPORT

### In brief

- Many artificial intelligence applications today are effectively “black boxes” lacking the ability to “explain” the reasoning behind their decisions.
- As AI expands into areas with large impact on people, such as health care, it will be critical to subject the technology to greater human scrutiny.
- Explainable AI won’t replace human workers; rather, it will complement and support people, so they can make better, faster, more accurate decisions.

# Data and Analysis plan

Cognitive and memory tests  
Evolution of 8 tests monitored  
across 6 time points  
(Follow-up: 3 years)

For each test, the **delta** of the scores between baseline (M0) and each available time point (**M6, M12, M18, M24, M30, and M36**) was calculated

**A total of 54 delta of scores of cognitive/memory tests was generated**

Genotyping: 486,137 variants (SNP) measured,  
295,995 present in at least 2 individuals  
retained for analysis

Remaining variants are then clustered together:  
2 genetic variants shared exactly by the same subjects are  
grouped together

**295,995 variants -> 288,651 clusters**

Variant status in subject's genome	Value in data
Absent	0
Heterozygous	1
Homozygous	2

# Data and Analysis plan

---

Neuro Imaging: brain metabolism, volume, connectivity, brain amyloid burden, and cortical thickness

Imaging descriptors were normalized using z-score, and the delta ratio of z-score between baseline (M0) and 24<sup>th</sup> month (M24) was calculated.

**A total of 301 delta ratio of neuroimaging variables were generated**


Blood based markers: A $\beta$  40, A $\beta$  42, A $\beta$  ratio, Bace1, NFL, Tau, YKL-40 at 2 time points

Blood based markers values were normalized using z-score, and the delta ratio of z-score between baseline (M0) and each available time point (M12/M18 and M24) were calculated.

# Data and Analysis plan

## Linking variants with evolution of scores

The number of relations that can be extracted from the data can be estimated to be  $6.6 \times 10^{11}$   
Within these,  $7.4 \times 10^8$  are the relations linking genetic variants to the following End Points:



# Results

**1,078 genes (1,158 variants) were selected**

Expressed in brain  
& Clinically relevant  
& Linked to an observed variation on, at least, one imaging biomarker

301 brain imaging descriptors,  
54 cognitive scores,  
14 blood based biomarkers

**Variants**  
(1158)



- Digit Span
- Frontal Assessment Battery
- Free and Cued Selective Reminding Test
- Rey Complex Figure
- Fluency
- Memory Binding Test
- Mini Mental State Examination
- Trail Making Test



- Brain Metabolism
- Brain Amyloid burden
- Brain Connectivity
- Brain Volume
- Cortical Thickness



- Aβ 40
- Aβ 42
- Aβ ratio
- Bace1
- NFL
- Tau
- YKL-40


Variant in rule must hit **all** 3 categories of endpoints

19 genetic variants  
involved in 26 relations



# Results

Cognitive function is maintained, while imaging biomarkers show negative evolution



*MMSE = Mini-Mental State Examination  
FAB = Frontal Assessment Battery  
DSMT = Digit Span Memory Test  
MBT = Memory Binding Test*



# Conclusion & Take Home Message

---

- An complex dataset, consisting of genomic, neuroimaging, cognitive tests and blood based markers, collected in a cohort of subject at risk, was successfully integrated and analyzed
- variants identified as linked **simultaneously** to multiple categories of endpoints: neuroimaging, cognitive tests and blood based markers
- **19 genetic variants** in 253 subjects suggest that compensatory mechanisms at the cell or tissue level brain to maintain cognitive function, despite structural modifications and accumulation of amyloid plaques
- **Artificial Intelligence and Association Rules** are powerful tools to uncover pertinent hypotheses from dataset extensively characterized using molecular and imaging descriptors
- More detailed analysis of **omic features linked to imaging data** will be presented by Dr F. Parmentier) **Thursday** at 11:45 515 AB - O5-07-04
- Application to **Exploring Gut Microbiota as a Source of Potential Biomarkers** (ANAVEX®2-73 Alzheimer's Disease Clinical Study) **Wednesday** 8:45 AM Concourse Hall 152 - O4-02-04

# Thank you

---

## **Professor Harald Hampel's Team**

**Sorbonne University  
Department of Neurology  
Institute of Memory and Alzheimer's Disease (IM2A)  
Brain & Spine Institute (ICM)  
François Lhermitte Building  
Pitié-Salpêtrière Hospital, Paris, France**

## **Ariana Pharma, Paris, France**

Mohammad Afshar  
Frédéric Parmentier  
Martin Kindermans  
Adrien Etcheto  
Coralie Williams

[www.arianapharma.com](http://www.arianapharma.com)

**Alzheimer Precision Medicine Initiative**

<https://www.apmiscience.com>



# Thank you



Diagnostics

